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Abstract
Background and Purpose: The major obstacles to treatment of pancreatic cancer are the highly invasive capacity and
resistance to chemo- and radiotherapy. Glycogen synthase kinase 3b (GSK3b) regulates multiple cellular pathways and is
implicated in various diseases including cancer. Here we investigate a pathological role for GSK3b in the invasive and
treatment resistant phenotype of pancreatic cancer.
Methods: Pancreatic cancer cells were examined for GSK3b expression, phosphorylation and activity using Western blotting
and in vitro kinase assay. The effects of GSK3b inhibition on cancer cell survival, proliferation, invasive ability and
susceptibility to gemcitabine and radiation were examined following treatment with a pharmacological inhibitor or by RNA
interference. Effects of GSK3b inhibition on cancer cell xenografts were also examined.
Results: Pancreatic cancer cells showed higher expression and activity of GSK3b than non-neoplastic cells, which were
associated with changes in its differential phosphorylation. Inhibition of GSK3b significantly reduced the proliferation and
survival of cancer cells, sensitized them to gemcitabine and ionizing radiation, and attenuated their migration and invasion.
These effects were associated with decreases in cyclin D1 expression and Rb phosphorylation. Inhibition of GSK3b also
altered the subcellular localization of Rac1 and F-actin and the cellular microarchitecture, including lamellipodia. Coincident
with these changes were the reduced secretion of matrix metalloproteinase-2 (MMP-2) and decreased phosphorylation of
focal adhesion kinase (FAK). The effects of GSK3b inhibition on tumor invasion, susceptibility to gemcitabine, MMP-2
expression and FAK phosphorylation were observed in tumor xenografts.
Conclusion: The targeting of GSK3b represents an effective strategy to overcome the dual challenges of invasiveness and
treatment resistance in pancreatic cancer.
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Introduction
Pancreatic cancer is a major health problem due to an overall 5-
year survival rate of less than 10% [1]. It is characterized by the
highly proliferative and invasive capacity of the tumor cells and a
strong predisposition for metastasis [2–4]. The aggressive nature of
pancreatic cancer hampers early diagnosis and curative surgical
intervention and renders it resistant to chemotherapy and
radiation [3,4]. The widely used therapy is infusional gemcitabine,
although fewer than 20% of patients respond to this treatment
[3,4]. Novel therapeutic strategies that enhance the effects of
gemcitabine and attenuate the invasive properties of pancreatic
cancer cells are needed. Molecular target-directed therapy has
emerged and includes targeting of the growth factor receptors,
angiogenic factor/receptor and matrix metalloproteinases, since
these are aberrantly expressed in pancreatic cancer [2–4]. Several
clinical trials of pancreatic cancer have already targeted these
growth factors, either as monotherapy or in combination with
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gemcitabine, but most have shown little or no therapeutic benefit
[5]. Identification of novel molecular targets that could enhance
the therapeutic effects of gemcitabine and radiation is therefore a
high priority [6].
Glycogen synthase kinase 3b (GSK3b) is a serine/threonine
protein kinase that regulates multiple signaling pathways [7].
Based on its known functions and involvement in primary
pathologies, GSK3b has been implicated as a therapeutic target
for glucose intolerance, neurodegenerative disorders and inflam-
mation [8]. We previously demonstrated that deregulated
expression, activity and phosphorylation of GSK3b are distinct
features of gastrointestinal cancers and glioblastoma and that
GSK3b sustains the survival and proliferation of these tumor cells.
A role for aberrant GSK3b in these tumor types is supported by
the observation that pharmacological inhibition of its activity
reduces the survival and proliferation of cancer cells and
predisposes them to apoptosis in vitro and in tumor xenografts
[9–12]. Although its role in cancer is still debated [13], the overall
results so far indicate that aberrant expression and activity of
GSK3b is a common and fundamental characteristic in a broad
spectrum of cancers (reviewed in [14]).
Based on earlier studies that demonstrated involvement of
GSK3b in NF-kB-mediated cell survival [15], GSK3b was found
to support the survival of pancreatic cancer cells via this pathway
[16,17]. Although GSK3b is a key regulator of cell polarization
and migration during physiological processes such as tissue
development and wound healing [18], very little is known about
its role in the migration and invasion of cancer cells. Here we
investigated the potential involvement of GSK3b in the invasive
nature of pancreatic cancer and its resistance to gemcitabine and




Written informed consent was obtained from all patients with
pancreatic cancer before surgery. This study was approved by the
Medical Ethics Committee of Kanazawa University.
Animal experiments were conducted according to the Guide-
lines for the Care and Use of Laboratory Animals in Kanazawa
Medical University, and in accordance with national guidelines for
animal use in research in Japan (http://www.lifescience.mext.go.
jp/policies/pdf/an_material011.pdf). The protocol was approved
by the Committee on Animal Experiments of Kanazawa Medical
University.
Cell Lines and Tissue Specimens
Human embryonic kidney cells (HEK-293) and pancreatic
cancer cells (PANC-1, MIA PaCa-2, BxPC-3, Capan-1) were
obtained from the American Type Culture Collection (ATCC).
These cell lines were characterized by DNA profiling in ATCC,
and passaged for fewer than 6 month after resuscitation. They
were maintained at 37uC with 5% CO2 in DMEM (HEK-293,
PANC-1, MIA PaCa-2, Capan-1) and RPMI 1640 (BxPC-3)
supplemented with 10% fetal bovine serum (FBS) and antibiotics
(penicillin G and streptomycin) (GIBCO). Cells were harvested
during the exponential growth phase for extraction of RNA and
protein.
This study included 15 patients with pancreatic cancer who
underwent surgery at the Department of Surgical Oncology,
Kanazawa University Hospital (Table S1). The surgical specimens
were fixed in neutral-buffered 10% formalin, embedded in
paraffin and processed for histopathologic diagnosis and immu-
nohistochemical examinations.
Western Blotting
Protein was extracted from cultured cells using lysis buffer
(CelLytic-MT, Sigma-Aldrich) containing a mixture of protease
and phosphatase inhibitors (Sigma-Aldrich). Concentrations of
protein extracts were measured by Coomassie Protein Assay
Reagents (Pierce). A 30 mg aliquot of protein was separated in
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and analyzed by Western blotting for the proteins of
interest and their phosphorylation [9,11,12] using the respective
primary antibodies (Table S2). Electroblotted membranes (Amer-
sham) were blocked with 5% bovine serum albumin prior to
detection of phosphorylated protein fractions. The amount of
protein in each sample was monitored by the expression of b-actin.
Signals were developed using enhanced chemiluminescence
(ECL).
In vitro Kinase Assay for GSK3b Activity
A nonradioisotopic in vitro kinase assay (NRIKA) [19] was used
to detect the activity of GSK3b derived from cells. The NRIKA
uses a sequential combination of immunoprecipitations to isolate
GSK3b in cellular protein samples, an in vitro kinase reaction that
uses recombinant human b-catenin protein (substrate) and non-
radioisotopic adenosine triphosphate (ATP), followed by immu-
noblotting to detect the b-catenin phosporylated at serine (S) 33,
S37 and/or threonine (T) 41 residues (p-b-cateninS33/37/T41) [19].
As a negative control, the mouse monoclonal antibody to GSK3b
was replaced by an equal amount of non-immune mouse IgG
(Sigma-Aldrich) in the immunoprecipitation step. GSK3b activity
is demonstrated by the presence of p-b-cateninS33/37/T41 in the
test reaction and by its absence in the negative control reaction.
The amount of immunoprecipitated GSK3b and the presence of
recombinant b-catenin protein in the kinase reaction were
monitored by immunoblotting.
Immunohistochemistry
Expression and/or phosphorylation of GSK3b, matrix metallo-
proteinase (MMP)-2 and focal adhesion kinase (FAK) in tumor
and adjacent non-neoplastic tissues of pancreatic cancer patients
were examined by the avidin-biotin-peroxidase complex method
[11,12]. Following deparaffinization, microwave antigen unmask-
ing and blocking of non-specific immunoreactions, paraffin
sections were incubated with antibody to GSK3b, tyrosine (Y)
216-phosphorylated GSK3b (p-GSK3bY216), MMP-2, FAK,
Y397-phosphorylated or Y861-phosphorylated FAK (p-FAKY397,
p-FAKY861) and p-b-cateninS33/37/T41, respectively. Sources and
working dilutions of these antibodies were shown in Table S2.
Sections were then incubated with biotinylated goat anti-rabbit
IgG or horse anti-mouse IgG (diluted 1:200; Vector). Immuno-
reactivity was detected using the ABComplex/HRP kit (DakoCy-
tomation). For the negative control, primary antibodies were
replaced by non-immune rabbit or mouse IgG (DakoCytomation).
Overexpression or higher phosphorylation of the respective
molecules in tumors was defined as stronger expression or
phosphorylation of either protein in the tumor cells compared to
non-neoplastic pancreatic ducts in the same patient.
Effects of GSK3b Inhibition on Cell Survival and
Proliferation
Cells seeded in 96-well plates were treated with dimethyl
sulfoxide (DMSO; Sigma-Aldrich) or a GSK3b inhibitor (AR-
Aberrant GSK3b in Pancreatic Cancer
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A014418; Calbiochem) dissolved in DMSO at the indicated final
concentrations in the medium. Notably, AR-A014418 does not
inhibit the activity of 26 closely related kinases and is considered
highly specific for GSK3b [20]. At designated time points, the
relative numbers of viable and proliferating cells were determined
by using WST-8 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tet-
razolio]-1,3-benzene disulfonate) assay kit (Cell counting kit-8;
Wako) and Cell Proliferation ELISA BrdU Kit (Roche), respec-
tively.
Small interfering RNA (siRNA) specific to human GSK3b
(GSK3b Validated Stealth RNAi) and negative control siRNA
(Stealth RNAi Negative Control Low GC duplex) were purchased
from Invitrogen. The GSK3b-specific siRNA targets the sequence
59-GCUCCAGAUCAUGAGAAAGCUAGAU-39. Cells were
transfected with 10 nM of either siRNA using Lipofectamine
RNAiMAX (Invitrogen). The effect of RNA interference on
GSK3b expression was determined by Western blotting using an
antibody against both GSK3a and b (Table S2). The specificity of
GSK3b-specific siRNA was confirmed in our previous studies
[11,12]. To examine the effect of GSK3b RNA interference on
cell survival and proliferation, cells seeded into 96-well plates were
transfected with 10 nM of control or GSK3b-specific siRNA. At
72 hrs after transfection, the relative numbers of viable and
proliferating cells were determined by the methods described
above.
Effects of GSK3b Inhibition on the Susceptibility of
Cancer Cells to Gemcitabine and to Ionizing Radiation
Cancer cells seeded into 96-well plates (3–66104 cells per well)
were treated with escalating concentrations of either gemcitabine
(Eli Lily) or AR-A014418. Following treatment for 72 hrs, the
relative number of viable cells was measured by WST-8 assay to
determine IC50 (50% cell survival inhibitory concentration) for
gemcitabine and AR-A014418 and to generate isobolograms.
Cells were then treated with a dose of gemcitabine close to IC50 in
the presence of DMSO or a low dose (5 or 10 mM) of AR-
A014418. The isobologram method [21] was used to determine
whether the effect of GSK3b inhibitor on pancreatic cancer cell
susceptibility to gemcitabine was additive, synergistic or antago-
nistic.
Figure 1. Expression, phosphorylation and activity of GSK3b in pancreatic cancer cells and primary pancreatic cancers. (A) Protein
extract from each cell line was analyzed by Western immunoblotting for the expression of GSK3b and its phosphorylation (p-GSK3bS9, p-GSK3bY216).
b-actin expression was monitored as a loading control. (B) GSK3b activity was detected by NRIKA [19] in the respective cells. As described in Materials
and Methods, GSK3b activity is demonstrated by the presence of p-b-cateninS33/37/T41 in the test reaction (T) and by its absence in the negative
control reaction (NC). The amount of immunoprecipitated GSK3b and the presence of substrate (b-catenin) in the kinase reaction were monitored by
immunoblotting. (C, D) Serial paraffin sections of a primary pancreatic cancer and its adjacent non-neoplastic tissue (patient No. 5 in Table S1) were
immunostained for GSK3b and p-GSK3bY216 (C), and for MMP-2, FAK, p-FAKY397 and p-FAKY861 (D). The scale bar in each panel indicates 100-mm in
length.
doi:10.1371/journal.pone.0055289.g001
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The effect of GSK3b inhibitor on pancreatic cancer cell
susceptibility to ionizing radiation was examined by colony-
forming cell survival assay. In each well of 6-well plates, 1,000
pancreatic cancer cells were seeded and treated sequentially with
either DMSO or a low dose (5 or 10 mM) of AR-A014418 for
24 hrs and with ionizing radiation at doses of 0, 4 and 8 Gy. At 6
days after irradiation, the total number of colonies stained with
0.1% crystal violet (Wako) was scored in each well. The mean
number of colonies in three separate experiments was calculated
with standard deviations.
Assays for Cell Migration and Invasion
Cancer cell migration and invasion were examined by
monolayer-based wound-healing assay and transwell assay.
Confluent monolayers of pancreatic cancer cells in the presence
of DMSO or AR-A014418 at a dose of 5 or 10 mM were scratched
with a 20 mL-micropipette tip to create a cell-free zone (wound). In
each condition, the gap distance between the wound edges was
monitored at three fixed reference points for 6 to 24 hrs by a CCD
camera (Axiocam MRm, Zeiss) connected to a phase-contrast
microscope (Axiovert 40 CFL, Zeiss). Cell migration at each time
point was calculated as the mean distance of wound measured at
the three points and compared between cells treated with DMSO
and AR-A014418.
Cell migration and invasion were examined by the transwell
assays using uncoated and matrigel-coated 24-well double-
chamber system (BD BioCoatTM MatrigelTM Incubation Cham-
ber, BD Bioscience). Cancer cells were suspended in serum-free
medium containing DMSO or AR-A014418 (5 or 10 mM), and
26104 cells were applied to the upper chamber pairing with the
lower chamber filled with medium containing 10% FBS (as a
chemo-attractant) and DMSO or AR-A014418 (5 or 10 mM). At
22 hrs after allowing cells to migrate and invade, cells on the lower
side of the chamber were fixed and stained with Diff-Quick Kit
(Symex). In each assay, the total number of cells per high-power
microscopic field on the lower side of the uncoated or matrigel-
coated chamber was counted and scored for migrating or invading
cells. The mean number of cells in five high-power microscopic
fields was calculated with standard deviations.
Cell Morphology and Immunofluorescence
Cytochemistry
Cancer cells grown on a cover slip were treated with either
DMSO or AR-A014418 (5 or 10 mM) for 12 hrs and then
Figure 2. Effects of GSK3b inhibition on the survival and proliferation of pancreatic cancer cells. (A) Relative numbers of viable cells at
the designated time points were measured by WST-8 assay for the respective cells in the presence of DMSO or AR-A014418 at the indicated
concentrations. (B) Relative numbers of viable cells were measured for the respective cells after transfection of non-specific (NS) or GSK3b-specific
siRNA. (C, D) The relative number of proliferating cells was determined by measuring the amount of BrdU incorporation. Proliferating cells were
scored at 48 hrs after treatment with DMSO or AR-A014418 (10 mM, 20 mM) (C), or after transfection with non-specific (NS) or GSK3b-specific siRNA
(D). Values shown in (A–D) are the means 6 SD of five separate experiments. *p,0.05, statistically significant difference between cells treated with
DMSO or AR-A014418 and between cells treated with non-specific and GSK3b-specific siRNA.
doi:10.1371/journal.pone.0055289.g002
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scratched as described above. At 12 hrs after scratching, the cells
along the wound edges were observed by phase-contrast micros-
copy. These cells were then fixed with 4% paraformaldehyde and
permeabilized with 0.1% Triton-X (Sigma-Aldrich). The cells
were incubated serially with mouse monoclonal antibody to Rac1
(BD Bioscience; diluted 1:200) at 4uC overnight and with Alexa
FlourH 488-labeled anti-mouse IgG (Invitrogen; diluted 1:1,000) at
room temperature for 40 min in the dark. After washing off excess
antibody, the cells were stained for filamentous (F-) actin with
Alexa FlourH 546-labeled phalloidin (Invitrogen; diluted 1:40) for
20 min. Then, cell nuclei were counterstained with Hoechst 33342
(Molecular Probes) and observed by fluorescence microscopy
(Keyence) for expression and subcellular localization of Rac1 and
F-actin.
Rac1 Activity
Protein was extracted from cells treated with DMSO or 10 mM
AR-A014418 for 24 hrs in 25 mM Tris-HCl buffer (pH 7.5)
containing 150 mM NaCl, 5 mM MgCl2, 1% NP-40, 1 mM
dithiothreitol and 5% glycerol. Active Rac1 was isolated from the
protein sample by the pull-down method using GST-human Pak1-
PBD (Thermo) and resins (Glutathione Sepharose 4 Fast Flow; GE
Healthcare). The fraction of Rac1 bound to guanosine triphos-
phate (GTP) (Rac1-GTP, an active form) was eluted from the
resins and detected by Western blot analysis using rabbit
polyclonal antibody to Rac1 (diluted 1:1,000; Thermo). Separate-
ly, whole cellular protein was probed for total Rac1 using the same
antibody.
Figure 3. Combined effect of gemcitabine or ionizong radiation and GSK3b inhibitor against cancer cells and xenografts. (A) The
influence of AR-A014418 on the effect of gemcitabine was analyzed using the isobologram [21] by plotting the IC50 of the combination therapy (Fig.
S2, Table S4). (B) The combined effect of ionizing radiation and AR-A014418 was tested in PANC-1 and MIA PaCa-2 cells by colony formation assay.
*p,0.05, statistically significant difference between cells treated with DMSO or AR-A014418. (C) The combined effect of gemcitabine and AR-A014418
was tested in PANC-1 xenografts. Athymic mice with PANC-1 xenograft were assigned to four groups for treatment with intraperitoneal injection
(twice a week) of DMSO (control; 8 mice), gemcitabine (GEM; 20 mg/kg body weight; 9 mice) and AR-A014418 (AR; 2 mg/kg body weight; 8 mice),
alone or in combination (GEM+AR; 9 mice). At the time after treatment for 10 weeks, tumor volume (cm3) was calculated using the formula 0.56S26L,
where S is the smallest tumor diameter (cm) and L is the largest (cm) [10,12]. The mean tumor volume was compared between the 4 groups. *p,0.05,
statistically significant difference between data.
doi:10.1371/journal.pone.0055289.g003
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Expression and Secretion of Matrix Metalloproteinase-2
(MMP-2)
Expression of MMP-2 mRNA was examined by quantitative
reverse transcription-PCR (qRT-PCR). Total RNA was isolated
from cells using ISOGEN (Wako). Complementary DNA (cDNA)
was generated using a Reverse Transcription Kit (Promega). qRT-
PCR was performed using SYBR Premix Ex TaqTMII (Takara
Bio) with the respective sets of sense and antisense primers for
amplification of MMP-2 and b-actin (Table S2) [11].
MMP-2 expression was analyzed by gelatin zymography [22].
Cancer cells were seeded on 12-well plates for 48 hrs and then
treated with DMSO or AR-A01418 (10 or 25 mM) for 24 hrs in
serum-free medium. Conditioned medium or treated cells were
incubated with SDS sample buffer for 30 min at 37uC. Samples
were separated on 10% SDS-PAGE containing 0.005% Alexa
Fluor 680-labelled gelatin. After electrophoresis, gels were washed
in 2.5% Triton X-100 for 2 hrs and then incubated in substrate
buffer overnight at 37uC. The gel was scanned by the LI-COR
Odyssey IR imaging system (Lincoln).
Tumor Xenograft Study
We prepared subcutaneous PANC-1 xenografts in mice as
described [23]. These mice were assigned to 4 groups and treated
with intraperitoneal injection (twice a week for 10 weeks) of
DMSO (diluent), gemcitabine (20 mg/kg body weight) and AR-
A014418 (2 mg/kg body weight, equivalent to 10 mM in culture
medium as determined and optimized in our previous studies
[10,12]) alone or in combination, respectively. All mice were
terminated after treatment and the xenograft tumors were
removed and processed for histological examination and immu-
nohistochemistry for expression of MMP-2 and FAK and
phosphorylation of FAK in tumor cells, as described above.
Statistical Analysis
Between-group statistical significance was determined using the
Student t test. In tumor xenograft study, tumor volumes in each
treatment group were expressed as means 6 standard deviation
(SD). The statistical significance of differences among the data was
determined with Kruskal Wallis H-test followed by Mann-
Whitney U-test with Bonferroni correction. A P value of ,0.05
was considered statistically significant.
Results
Expression, Phosphorylation and Activity of GSK3b in
Cancer Cells
Pancreatic cancer cells showed higher basal levels of GSK3b
and the Y216-phosphorylated active form (p-GSK3bY216) and
lower levels of the S9-phosphorylated inactive form (p-GSK3bS9)
compared to HEK 293 cells (Fig. 1A). Cancer cell-derived GSK3b
was active for phosphorylation of its substrate, b-catenin (Fig. 1B).
These results indicate that pancreatic cancer cells express active
GSK3b that is not regulated by differential phosphorylation at S9
and Y216. Immunohistochemistry for the serial sections showed
that GSK3b and p-GSK3bY216 were diffusely expressed and
colocalized in the tumor cells and overexpressed in the invasive
tumor cells of 8/15 (53%) pancreatic cancer patients (Fig. 1C).
Overexpression was more frequent in patients with T3/T4
primary tumor or with lymph node and distant metastasis at the
time of surgery (Table S1).
Effects of GSK3b Inhibitor on Cell Survival and
Proliferation
We investigated whether GSK3b contributes to cancer cell
survival and proliferation. The levels of glycogen synthase (GS)
phosphorylated at Y641 (p-GSS641) and p-b-cateninS33/37/T41
decreased in cancer cells following treatment with AR-A014418
(Fig. S1A, B), indicating its activity against GSK3b in cancer cells.
Figure 4. Changes in expression and phosphorylation of the
proteins in cancer cells following GSK3b inhibition. (A)
Immunoblotting analysis compares the expression of Rb, CDK4, CDK6
and cyclin D1, and the phosphorylation of Rb at S780 and S807/811
residues (p-RbS780, p-RbS807/811) between cells treated with DMSO (DM)
or 10 mM AR-A014418 (AR) for 24 hrs. (B) Changes in levels of p-RbS780
and p-RbS807/811 and expression of Rb and cyclin D1 were examined in
MIA PaCa-2 cells at the indicated time points after treatment with
10 mM AR-A014418. (C) Expression of Rb, cyclin D1, GSK3a and GSK3b
proteins and levels of Rb phosphorylation (p-RbS780) were examined
and compared between the same pancreatic cancer cells transfected
with non-specific siRNA (NS) or GSK3b-specific siRNA (S) (10 nM each).
(A–C) b-actin expression was monitored as a loading control.
doi:10.1371/journal.pone.0055289.g004
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GSK3b inhibition attenuated the survival and proliferation of
cancer cells (Fig. 2A, C). Depletion of GSK3b by RNA
interference attenuated cell viability and proliferation in all cancer
cell lines (Fig. 2B, D). These results are consistent with the previous
studies [16,17] suggesting that aberrant GSK3b impacts upon the
survival and proliferation of pancreatic cancer cells.
Effects of GSK3b Inhibitor Combined with Gemcitabine
or Radiation Against Cancer Cells
The above results led us to address whether GSK3b inhibition
could enhance the effects of gemcitabine and ionizing radiation.
High doses (25 or 50 mM) of AR-A014418 alone had a therapeutic
effect against cancer cells (Fig. 2A, C). Therefore, the effects of
relatively low doses (5 or 10 mM) were tested in combination with
gemcitabine or ionizing radiation. First, we examined dose-
dependent effects of AR-A014418 and gemcitabine on cancer cell
survival and determined their IC50 values (Fig. 2A, Fig. S2). IC50
values for AR-A014418 were similar in PANC-1, MIA PaCa-2
and BxPC-3 cells, whereas those for gemcitabine varied (Table
S3). We next examined the effect of AR-A014418 on the
susceptibility of cancer cells to gemcitabine. When cells were
treated with escalating doses (1 ng/mL to 10 mg/mL) of
gemcitabine, combination with low dose AR-A014418 significant-
ly reduced the IC50 of gemcitabine (Fig. S2, Table S4).
Isobologram analysis [21] of the data revealed that low-dose
AR-A014418 in combination with gemcitabine was additive
against PANC-1 cells and synergistic against MIA PaCa-2 cells
(Fig. 3A). We confirmed that the combined treatment with AR-
A014418 significantly enhanced the effect of gemcitabine against
cancer cell xenografts (Fig. 3C) in rodents with no detrimental
effects by the reagent.
The effect of AR-A014418 combined with ionizing radiation
was tested in cancer cells. In colony-forming cell survival assay,
presence of 10 mM AR-A014418 significantly reduced viability of
the cancer cells compared to treatment with ionizing radiation
alone (Fig. 3B). Together, these results demonstrate that combined
treatment with GSK3b inhibitor sensitizes cancer cells to
gemcitabine and to ionizing radiation.
Molecular Alterations Associated with GSK3b Inhibition
in Cancer Cells
To understand the mechanism that underlies involvement of
GSK3b in cancer cell proliferation and resistance to therapy, we
investigated the effect of GSK3b inhibition on expression and
phosphorylation of proteins involved in cell cycle regulation and
proliferation. Consistent with previous studies (reviewed in [2]),
pancreatic cancer cells showed phosphorylation of Rb protein (p-
RbS780, p-RbS807/811; Fig. 4), suggesting that binding to the E2F
Figure 5. Effects of GSK3b inhibition on the migration and invasion of pancreatic cancer cells. (A) Upper panels show the time course for
PANC-1 cell migration in a wound-healing assay in the presence of DMSO or AR-A014418 (AR). The lower panel shows the relative widths of wounds
measured as a percentage of the initial gap at time zero. *p,0.05, statistically significant difference between cells treated with DMSO or AR-A014418.
(B) Migrating cells through uncoated transwell and invading cells through matrigel-coated transwell were scored for PANC-1 and MIA PaCa-2 cells
treated with DMSO or AR-A014418 (AR) for 22 hrs. Representative photomicroscopic findings in each assay are shown below the columns. *p,0.05,
statistically significant difference between cells treated with DMSO or AR-A014418.
doi:10.1371/journal.pone.0055289.g005
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Figure 6. Changes in the invasive phenotype of pancreatic cancer cells following GSK3b inhibition. (A) Phase-contrast microscopic
findings (left panels), expression and subcellular localization of F-actin and Rac-1 (middle panels) and their merged images (right panels) in cancer
cells along the wound edge (dashed line) were observed in the wound-healing assay in the presence of DMSO or AR-A014418 (AR). Arrows indicate
lamellipodia. (B) Changes in the levels of active (Rac1-GTP) and total Rac1 examined by pull-down assay and Western blotting between the cancer
cells treated with DMSO (DM) or 10 mM AR-A014418 (AR) for 24 hrs. (C) Changes in the secretion and mRNA expression of MMP-2 examined by
gelatin zymography (left panel) and qRT-PCR (right panel) between PANC-1 cells treated with DMSO (DM) or AR-A014418 (AR) for 24 hrs. Values for
the relative levels of mRNA expression are shown as means 6 SDs of four separate experiments. *p,0.05, statistically significant difference between
cells treated with DMSO or AR-A014418. (D) Changes in the expression of FAK and its phosphorylation (p-FAKY397, p-FAKY861) examined by Western
blotting in cancer cells following GSK3b inhibition. The cells in confluent monolayer were wounded multiple times and cultured in the presence of
DMSO (DM) or 10 mM AR-A014418 (AR) for 24 hrs. b-actin expression was monitored as a loading control.
doi:10.1371/journal.pone.0055289.g006
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transcription factor was impaired [24]. Treatment with either AR-
A014418 or GSK3b-specific siRNA decreased the levels of Rb
phosphorylation and cyclin D1 expression (Fig. 4), however no
consistent changes were found for CDK4 or CDK6 expression.
Effects of GSK3b Inhibition on Cancer Cell Migration and
Invasion
The wound-healing assay showed that migration of cancer cells
was significantly reduced by treatment with 5 mM and 10 mM AR-
A014418 (Fig. 5A, Fig. S3). Importantly, these concentrations
were insufficient to inhibit cell proliferation 24 hrs after treatment
(Fig. 2A). In the transwell assay, 5 mM and 10 mM AR-A014418
inhibited chemotactic migration of cancer cells and their invasion
of extracellular matrix component (Fig. 5B).
Changes in the Invasive Phenotype of Cancer Cells
Following GSK3b Inhibition
The above results led us to hypothesize that GSK3b has a role
in cancer cell migration and invasion. This may be attributed to
epithelial-mesenchymal transition (EMT), a phenotype responsible
for cancer cell invasion and metastasis [25]. We investigated
expression of the EMT-related molecules E-cadherin, N-cadherin
and vimentin in cancer cells following treatment with AR-A04418
and GSK3b-specific siRNA. No consistent changes were observed
in the levels of expression of these molecules (Fig. S1C, D),
implying that EMT is unlikely to be the mechanism by which
GSK3b inhibition attenuates cancer cell migration and invasion.
A possible explanation may be that established cancer cell lines
have already acquired the EMT phenotype.
We next focused on cellular microarchitecture and in particular
on lamellipodia that plays an important role in cell migration
during physiological processes and in cancer cell migration and
invasion [26]. A member of the Rho-GTPase family, Rac1,
participates in lamellipodia formation and in cancer progression
[27]. Wound healing assay showed that migrating cancer cells
form lamellipodia at the site of Rac1 localization, with actin
filaments organizing the lamella structure. Treatment with AR-
A014418 decreased lamellipodia formation in cancer cells at the
wound edge and resulted in diffuse cytoplasmic distribution of
Rac1 and F-actin (Fig. 6A). Concomitant with these changes,
treatment with AR-A014418 decreased the Rac1-GTP (active
form) in cancer cells stimulated to multiply by the regenerating
wounds (Fig. 6B).
Rac1 was reported to increase the secretion and activity of
MMP-2 in cancer cells [28]. Treatment with AR-A014418
inhibited MMP-2 secretion and decreased MMP-2 mRNA
expression (Fig. 6C). These results indicate a mechanistic link
between GSK3b and Rac1 in the regulation of MMP-2 expression
and secretion. Previous studies have reported that FAK regulates
Figure 7. Changes in the invasive phenotype of pancreatic cancer cells in xenografts following GSK3b inhibition. (A) The left two
panels showed represntative histological findings of the deeper part of PANC-1 xenografts in rodents after treatment with intraperitoneal injection
(twice a week) of DMSO and AR-A014418, respectively, as shown in Fig. 3C. The serial sections of these tumors were immunostained for MMP-2, FAK,
p-FAKY397 and p-FAKY861. Closed triangles in the lower panels delineate an interface between the xenograft and host stromal tissue. (B) These tumors
were immunostained for GSK3b, p-GSK3bY216 and b-catenin. (A, B) The scale bar in each panel indicates 100-mm in length.
doi:10.1371/journal.pone.0055289.g007
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Rac1 [29]. We therefore investigated the effect of GSK3b
inhibition on FAK activity in cancer cells responding to wound
stimulation by determining the levels of p-FAKY397 and p-
FAKY861 [29]. FAK phosphorylation was detected in cancer cells
stimulated by multiple wounds. Treatment with 10 mM AR-
A014418 reduced the levels of p-FAKY397 and p-FAKY861
(Fig. 6D), suggesting a pivotal role for the GSK3b/FAK/Rac1
pathway in promoting pancreatic cancer cell invasion.
Immunohistochemical examination of the primary pancreatic
cancers showed higher expression of MMP-2 and FAK and
tyrosine phosphorylation of FAK in tumor cells than non-
neoplastic pancreatic ducts (Fig. 1D). In histological examination
of the deep part of cancer cell xenografts, the tumor in mice
treated with AR-A014418 showed less invasive than those in sham
(DMSO)-treated mice (Fig. 7A, left panels). Immunohistochemis-
try showed decreases in MMP-2 expression and FAK phosphor-
ylation in the tumors by treatment with AR-A014418 (Fig. 7A).
Both groups of mice showed the similar levels of GSK3b
expression in tumor xenografts (Fig. 7B, left panels). In AR-
A014418-treated mice, Y216-phosphorylation of GSK3b ap-
peared to decrease in the tumors, and membranous expression,
but no nuclear accumulation of b-catenin was observed in tumor
cells (Fig. 7B).
Discussion
Failure of treatments for pancreatic cancer is due to the high
propensity of these tumors to invade surrounding tissues and
because of their resistance to chemotherapy and radiation [3,4].
The present study confirmed previously reported roles for GSK3b
in cancer cell survival and proliferation [16,17]. However, the
novel findings of this study relate to the effects of GSK3b
inhibition on the invasive ability and phenotype of pancreatic
cancer cells and on their susceptibility to gemcitabine and
radiation. The results provide a biological rationale for combina-
tional treatment strategies that include targeting of GSK3b in
order to control refractory pancreatic cancer.
The proinvasive phenotype of cancer cells includes EMT and
increased cell motility [25,26]. Here, we found overexpression of
GSK3b and its active form in the tumor cells in the invasive
primary pancreatic cancers. Inhibition of GSK3b attenuated
cancer cell migration and invasion in wound-healing and transwell
assays. No consistent changes were observed for the expression of
EMT-related molecules in cancer cells treated with GSK3b
inhibitor, in contrast to a previous study that found GSK3b
inhibits EMT by phosphorylating and destabilizing snail, a
transcriptional repressor of E-cadherin [30]. Our study suggests
that EMT may not be involved in the mechanism by which
GSK3b inhibition attenuates cancer cell migration and invasion.
In wound-healing assays, the migrating cancer cells formed
lamellipodia where Rac1 and F-actin preferentially co-localized.
Treatment with GSK3b inhibitor decreased lamellipodia forma-
tion and re-distributed Rac1 and F-actin throughout the
cytoplasm. GSK3b inhibition decreased the active fractions of
FAK and Rac1 and the expression and secretion of MMP-2.
These findings indicate for the first time the existence of a key
pathway involving GSK3b, FAK and Rac1 that plays a pivotal
role in promoting pancreatic cancer invasion and could provide a
novel target for inhibiting cancer cell invasion.
Rac1 cycles between active GTP-bound and inactive guanosine
diphosphate (GDP)-bound forms. Rho-GTPase activity is regulat-
ed by three classes of proteins including guanine nucleotide
exchange factors (GEFs), GTPase-activating proteins (GAPs) and
GDP dissociation inhibitors [27]. GEFs that activate GTPases
participate in cancer progression and are considered as therapeutic
targets [31]. Aberrant expression of Vav1, a Vav family member
of GEFs, is frequently observed in pancreatic cancer and
associated with active Rac1 and worse prognosis [32]. Within
the cell migration machinery, the IQ motif-containing GAPs
(IQGAPs) form scaffolds with Rac1 and Cdc42 (another member
of Rho-GTPases) and bind to F-actin. In migrating cells, this
molecular complex localizes to actin-rich cellular structures such
as lamellipodia and controls F-actin and microtubule dynamics
[33]. GSK3b regulates microtubule stability by phosphorylating
microtubule-binding proteins, while Cdc42 and GSK3b interact
spatially to dictate the polarity of migrating cells [34,35]. IQGAPs
participate in cancer cell invasion and the overexpression of
IQGAP1 is associated with unfavorable prognosis in various
cancers [36,37]. A previous study indicated that Rac1 destabilizes
E-cadherin-mediated cell adhesion in pancreatic cancer by
interacting with IQGAP1, thereby promoting cancer cell migra-
tion [38]. Further work is required to clarify the putative roles for
GSK3b in regulating cytoskeletal structure, cell polarity and
motility and its promotion of cancer cell migration and invasion.
Resistance of cancer cells to chemotherapeutic agents, radiation
and molecular target-directed agents is a critical determinant of
outcome from recurrent and unresectable pancreatic cancer [3–5].
Many studies have investigated the mechanisms by which
pancreatic cancer cells resist or acquire resistance to chemother-
apy and radiation, focusing mainly on NF-kB [39]. GSK3b was
reported to sustain pancreatic cancer cell survival by maintaining
the transcriptional activity of NF-kB [16,17]. However, a recent
study found that disruption of NF-kB activity through GSK3b
inhibition did not sensitize cancer cells to gemcitabine [40].
Whereas these studies examined the activity of exogenous
(transfected) NF-kB, we previously found no effect of GSK3b
inhibition on endogenous NF-kB transcriptional activity in
gastrointestinal cancers (including pancreatic cancer) and glioblas-
toma [11,12]. Therefore, a role for GSK3b in regulating NF-kB
activity in cancer cells remains controversial.
In the present study, we tested various combinations and doses
of gemcitabine and AR-A014418 on the survival of pancreatic
cancer cells. AR-A014418 sensitized the cells to gemcitabine when
the doses of both agents were individually optimized. Consistent
with our preliminary study [23], the present study confirmed the
effect of this drug combination in the cancer cell xenografts.
Elucidation of the underlying biological mechanism is important
to justify the combinational treatment of GSK3b inhibitor with
gemcitabine. One possible mechanism is suggested by our
observation that GSK3b inhibition decreased Rb phosphoryla-
tion, thus restoring its function against E2F. Ribonucleotide
reductase (RR), thymidylate synthase (TS) and thymidine kinase
(TK) are transcriptional targets for E2F and essential for DNA
synthesis and replication [41]. It was reported that pancreatic
cancers with increased RR expression are resistant to gemcitabine
[42]. Therefore, restoration of Rb ability to bind to E2F following
GSK3b inhibition may sensitizes cancer cells to gemcitabine by
affecting RR expression. Inhibition of GSK3b also enhanced the
effect of ionizing radiation against cancer cells. Decreases in E2F-
dependent transcription of TS and TK may be responsible for this
radio-sensitization effect via the impairment of radiation-induced
DNA damage repair. In contrast to our result, a recent study
reported that siRNA-mediated GSK3b silencing promotes pan-
creatic cancer cell survival following irradiation via stabilization
and activation of b-catenin [43]. Clarification of the role of
GSK3b in modulating the anti-tumor effects of radiation is
therefore a priority for future investigations.
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While the levels of GSK3b activity differ between the pancreatic
cancer cells examined in this study (Fig. 1B), its inhibitor AR-
A014418 has the similar IC50 values against them (Fig. 2A, Table
S3). This is consistent with our previous studies showing the similar
therapeutic effects of this inhibitor in its pharmacologic doses [20]
against different gastrointestinal cancer cells [9,12] and glioblas-
toma cells [11]. Other studies also reported the similar result in
pancreatic cancer cells [16,17]. These studies may suggest that
survival of different cancer cells and/or their susceptibility to AR-
A014418 might similarly depend on GSK3b activity in cells. This
issue should be an important future task for cancer treatment
targeting GSK3b.
Several studies have suggested opposite roles for GSK3b in the
same cellular events mediated by the protooncoproteins and tumor
suppressors between non-neoplastic and cancer cells [14].
Whereas GSK3b phosphorylates and stabilizes p27Kip1 in normal
cells [44], it down-regulates p27Kip1 in leukemia cells and
selectively maintains the survival and proliferation of these cells
[45]. Despite its role in destabilizing cyclin D1 in physiological
cells [7,8,13], inhibition of GSK3b decreases cyclin D1 expression
in cancer cells [11,12,46]. Other studies reported various roles for
GSK3b in regulating cell stemness. It was shown that GSK3b
inhibition maintains the pluripotency of embryonic stem cells and
the repopulation of hematopoietic stem cells through activation of
the Wnt and hedgehog pathways, respectively [47,48]. Conversely,
it was reported that GSK3b sustains tumor cell stemness in
leukemia and glioblastoma [45,49]. Our present and previous
studies showing the presence of both inactive (p-GSK3bS9) and
active (p-GSK3bY216) forms in non-neoplastic cells and tissues
[9,12] suggest that the kinase activity is regulated by differential
phosphorylation in these key residues depending on stimuli in cells
of non-neoplastic origin. Although the underlying mechanisms are
yet to be understood, differential roles for GSK3b in normal and
neoplastic cells could be advantageous for cancer treatment
strategies that target this kinase. Consistently, the animal studies
showed little detrimental effects of GSK3b inhibition on normal
cells and vital organs [10,12,23], leading to promotion of future
clinical application of cancer treatment targeting GSK3b.
Concerns regarding the therapeutic use of GSK3b inhibitors
remain, because these may activate oncogenic (e.g., Wnt) signaling
and thus promote cellular transformation [7,8,13]. Unlike this
hypothesis, inhibition of GSK3b is not sufficient to stabilize b-
catenin in normal cells and this seems to occur only when other
transforming events (eg., adenomatous polyposis coli [APC]
protein truncation) have already taken place [50]. In normal cells,
the known function of GSK3b in mediating Wnt/b-catenin
signaling depends on cell membrane-associated fraction of GSK3b
that antagonizes the phosphorylation of b-catenin by cytoplasmic
GSK3b, a key step initiating b-catenin degradation [51]. These
paradoxical roles of GSK3b in cells partly supports the reports
showing that GSK3b inhibition does not influence the survival or
growth of normal cells, nor induce their transformation
([9,12,16,19]; reviewed in [14]). Consistently the above concerns
have not deterred preclinical studies of GSK3b inhibitors for the
treatment of many cancer types [14], or Phase II clinical trials for
the treatment of neurological diseases [52]. These trials are
rationally supported by the differential roles of GSK3b in cellular
signaling events between normal and tumor cells and by the
phosphorylation-dependent regulation of GSK3b activity that
presumably protects normal cells from transformation by GSK3b
inhibition [9–12,14]. Currently, two clinical trials are being
undertaken to test whether the GSK3b inhibitor LY2090314
(Eli Lily) enhances the efficacy of established chemotherapeutic
agents for advanced solid cancers (http://clinicaltrials.gov/ct2/
show/study/NCT01287520) and leukemia (http://clinicaltrials.
gov/ct2/show/study/NCT01214603).
Supporting Information
Figure S1 Effects of GSK3b inhibition on expression and
phosphorylation of the proteins in pancreatic cancer
cells. The levels of expression and phosphorylation of the
indicated proteins were examined by Western blotting in
pancreatic cancer cells after treatment with the respective agents.
(A, B) Expression of GS and b-catenin and their phosphorylation
(p-GSS641, p-b-catenin S33/37/T41) were examined and compared
between the same pancreatic cancer cells treated with DMSO
(DM) or 10 mM AR-A014418 (AR) for 6 hrs. (C) Expression of E-
cadherin, N-cadherin and vimentin in pancreatic cancer cells
treated with DMSO (DM) or 10 mM AR-A014418 (AR) for 6 hrs.
(D) Expression of E-cadherin, N-cadherin, vimentin and GSK3a
and GSK3b in pancreatic cancer cells transfected with non-
specific siRNA (NS) or GSK3b-specific (S) siRNA (10 nM each).
(A–D) The amount of protein extract in each sample was
monitored by expression of b-actin.
(TIF)
Figure S2 Effects of gemciatbine and AR-A014418, alone
or in combination, against pancreatic cancer cells.
Inhibitory effects of gemcitabine, AR-A014418 and combinations
of the two agents at different doses were examined on the survival
of pancreatic cancer cells. PANC-1 (A) and MIA PaCa-2 (B) cells
were treated with escalating doses of either gemcitabine, AR-
A014418 or both agents in combination at the doses indicated.
Relative (%) cell survival ratios for each cell line were examined by
WST-8 assay at 48 hrs after treatment with the respective agent.
IC50 of gemcitabine in the absence (+ DMSO) or presence of AR-
A014418 (+ AR) at the indicated doses was determined and is
shown in Table S4.
(TIF)
Figure S3 Effect of GSK3b inhibitor on pancreatic
cancer cell migration. The time course for cell migration
was minitored by monolayer-based wound healing assay for MIA
PaCa-2 and BxPC-3 cells in the presence of DMSO or AR-
A014418 (AR 5 mM, AR 10 mM). The relative widths of wounds
were measured and expressed as a percentage of the initial gap at
time zero. Values are means 6 SD of three separate experiments.
*p,0.05, statistically significant difference between cells treated
with DMSO or AR-A014418.
(TIF)
Table S1 Clinical and pathologic characteristics of
patients with pancreatic cancer.
(DOC)
Table S2 Primary antibodies used for Western blotting
and Sequences of the primers used for RT-PCR
amplification.
(DOC)
Table S3 Comparison of IC50 values of gemcitabine and
a GSK3b inhibitor (AR-A014418) between pancreatic
cancer cell lines (PANC-1, MIA PaCa-2 and BxPC-3).
(DOC)
Table S4 Changes in 50% cell survival inhibitory
concentration (IC50) of gemcitabine in combination with
different doses of AR-A014418 in pancreatic cancer.
(DOC)
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